Meta-analysis of 20 mostly non-randomised studies (396 patients) of neoadjuvant immune checkpoint inhibitors in localised dMMR/MSI-H gastric or GEJ cancer: pooled pathological complete response 41.9% and grade 3-4 immune-related adverse events 6.7%.
Meta-analysisn = 396 patients
Schwengber et al. Neoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric cancer: a meta-analysis